Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC1 | P33527 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1959761 | 1.00 | ABCC1 (0.34) | ABCC1MCHR1ALDH1A1LMNAMAPT | |
| SCHEMBL9978056 | 0.83 | ADCY6 (0.37) | ABCC1MCHR1ALDH1A1LMNAMAPT | |
| SCHEMBL9968469 | 0.83 | — | — | |
| SCHEMBL1333630 | 0.83 | — | — | |
| SCHEMBL1331968 | 0.81 | — | — | |
| SCHEMBL1331818 | 0.80 | TP53 (0.33) | MCHR1KDM4EDGAT1 | |
| SCHEMBL1962783 | 0.79 | ALDH1A1 (0.38) | MCHR1ALDH1A1LMNAMAPTDGAT1 | |
| SCHEMBL8772291 | 0.79 | ALDH1A1 (0.38) | MCHR1ALDH1A1LMNAMAPTDGAT1 | |
| SCHEMBL6113620 | 0.76 | P2RY14 (0.40) | MCHR1ALDH1A1LMNAMAPT | |
| SCHEMBL8772192 | 0.76 | P2RY14 (0.40) | MCHR1ALDH1A1LMNAMAPTDGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651913-B1 | INDENO-FUSED RING COMPOUNDS HAVING PHOTOCHROMIC PROPERTIES | TRANSITIONS OPTICAL INC (US) | 2017-04-19 | — | — | EP | disclosed |
| US-9309455-B2 | Indeno-fused ring compounds | TRANSITIONS OPTICAL, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9309455-B2 | Indeno-fused ring compounds | TRANSITIONS OPTICAL, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| EP-2652552-B9 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | TRANSITIONS OPTICAL INC (US) | 2016-02-17 | — | — | EP | disclosed |
| EP-2652552-B1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | TRANSITIONS OPTICAL INC (US) | 2015-09-02 | — | — | EP | disclosed |
| US-20140166948-A1 | INDENO-FUSED RING COMPOUNDS | TRANSITIONS OPTICAL LIMITED (IE) | 2014-06-19 | — | — | US | disclosed |
| US-20140166948-A1 | INDENO-FUSED RING COMPOUNDS | TRANSITIONS OPTICAL LIMITED (IE) | 2014-06-19 | — | — | US | disclosed |
| EP-2652552-A1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | Transitions Optical, Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| US-8545984-B2 | Photochromic compounds and compositions | TRANSITIONS OPTICAL, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| WO-2012082299-A1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | TRANSITIONS OPTICAL, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| US-20120126185-A1 | INDENO-FUSED RING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120126185-A1 | INDENO-FUSED RING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20110140056-A1 | Indeno-fused ring compounds | TRANSITIONS OPTICAL, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110140056-A1 | Indeno-fused ring compounds | TRANSITIONS OPTICAL, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110129678-A1 | Photochromic compounds and compositions | TRANSITIONS OPTICAL, INC. (US) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110140056-A1 | Indeno-fused ring compounds | CRY2, SQOR, INTS6 | ABCC1 3242/4885MCHR1 3285/4885ALDH1A1 498/4885 |
| US-20110129678-A1 | Photochromic compounds and compositions | CRY2, CRY1, PPOX | ABCC1 2009/4885MCHR1 2392/4885ALDH1A1 1243/4885 |
| US-20120126185-A1 | INDENO-FUSED RING COMPOUNDS | CRY2, SQOR, INTS6 | ABCC1 3242/4885MCHR1 3285/4885ALDH1A1 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.